ACTRN12612000368831已完成未知
A multi-centre, randomized, controlled study to evaluate the effectiveness of pharmacist-led multidisciplinary system-change smoking cessation intervention in comparison with usual care for smokers admitted to public hospitals.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Age 18 years and above, who are smokers at the time of hospital admission and available for follow-up on discharge, and at 1, 6, and 12 months post-discharge
排除标准
- •Physical or mental inability to participate in the study, unable to provide written informed consent, unable to communicate in English, terminal illness, pregnancy and on another smoking cessation therapy or program at the time of hospital admission
研究者
相似试验
进行中（未招募）
1 期
Combined treatement with human albumin and intravenous immunoglobulin in Alzheimer diseaseEUCTR2011-001598-25-ESINSTITUTO GRIFOLS, S.A.350
招募中
3 期
BAX602-PEDCongenital Heart DiseaseJPRN-jRCT2032220540akano Toshihide30
招募中
1 期
Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with AcromegalyMedDRA version: 20.0Level: PTClassification code 10000599Term: AcromegalySystem Organ Class: 10014698 - Endocrine disordersAcromegalyEUCTR2020-005431-70-BECrinetics Pharmaceuticals, Inc.52
招募中
3 期
A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands.E220 Acromegaly and pituitary gigantismAcromegaly and pituitary gigantismE220PER-043-21Crinetics Pharmaceuticals, Inc.1
进行中（未招募）
1 期
Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with AcromegalyAcromegalyEUCTR2020-005431-70-ATCrinetics Pharmaceuticals, Inc.52